Generic Medicine Info
Baseline neutrophil count of <1,500 cells/mm3. Severe hepatic impairment.
Special Precautions
Patient w/ severe fluid retention, resp disorders, eye disorders. Renal and mild to moderate hepatic impairment. Pregnancy and lactation. Patient Counselling May cause symptoms of alcohol intoxication. May impair ability to drive or operate machinery. Monitoring Parameters Monitor haematologic, hepatic and renal functions; monitor for hypersensitivity reactions, neurosensory symptoms, GI toxicity, cutaneous reactions, visual impairment, fluid retention, epiphora, and canalicular stenosis; baseline cardiac assessment and cardiac function monitoring in patients given docetaxel w/ other cytotoxic drugs esp trastuzumab.
Adverse Reactions
Fluid retention, localised erythema of extremities, severe neurosensory symptoms, cystoid macular oedema, severe asthenia,, infections, anaemia, thrombocytopenia, neuropathy, dysgeusia, constipation, anorexia, nail disorders, pain, nausea, diarrhoea, vomiting, mucositis, alopecia, skin reactions, myalgia; resp disorders (e.g. dyspnoea, acute pulmonary oedema, acute resp distress syndrome/pneumonitis, interstitial lung disease, interstitial pneumonia, pulmonary fibrosis), acute myeloid leukemia, renal failure.
Potentially Fatal: Toxic deaths, hepatotoxicity, neutropenia, severe hypersensitivity reactions (e.g. anaphylaxis), resp failure, tumour lysis syndrome, heart failure (when given w/ other cytotoxic drugs esp trastuzumab).
Drug Interactions
CYP3A4 inducers, inhibitors, or substrates may alter docetaxel metabolism.
CIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01CD02 - docetaxel ; Belongs to the class of plant alkaloids and other natural products, taxanes. Used in the treatment of cancer.
Disclaimer: This information is independently developed by CIMS based on docetaxel from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in